Article Details
Retrieved on: 2022-10-26 19:55:44
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
“Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca's next-generation oral selective estrogen receptor degrader ( ...
Article found on: www.financialexpress.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here